Developer docs
API playgroundTry for free, no card

Search company profiles

Qureight

Full company profile

uuid0000b3e

Namestring
Qureight
Legal namestring
Qureight Limited
Websiteurl
qureight.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Qureight is a Cambridge-headquartered AI-powered imaging contract research organization (CRO) that delivers deep-learning quantitative imaging biomarkers and trial-operations services to global biopharma sponsors developing therapies for lung and heart disease. Its proprietary platform processes standard-of-care inspiratory CT and CTPA scans through a suite of 3D volumetric convolutional neural networks branded as Fibr8 (fibrosis), Glass8 (inflammation), Air8 (airways), Vascul8 (pulmonary vasculature) and Lung8 (whole-lung and lobar volumes), each registered as a UK trademark and validated in peer-reviewed publications with a 98.4% successful CT analysis rate. The company also licenses what it describes as some of the largest real-world clinical and imaging datasets in idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, pulmonary hypertension and bronchiectasis, built through NHS and global data contracts and supplemented by OSIC membership, to support synthetic control arms, cohort enrichment, exploratory partnerships and enrolled-cohort reporting.

The offering is organised into three product lines: global imaging CRO services (image management, central reads, site onboarding, trial read-outs), AI-powered endpoints and analytics (the biomarker suite plus real-time enrolment analytics), and data science products (synthetic control arms, cohort enrichment, enrolled cohort reporting, exploratory partnerships). Revenue is generated through enterprise, quote-based contracts with global pharmaceutical and biotech sponsors; pricing is not publicly disclosed. Commercial momentum is evidenced by a customer base of 17+ named biopharma sponsors — including AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, MSD, Vicore Pharma, Avalyn, Mediar, Calluna, Rein Therapeutics, Cumberland Pharmaceuticals, Insilico Medicine and Endeavor BioMedicines — across multiple Phase 2 programmes in IPF, PPF, PH, systemic sclerosis and bronchiectasis. The company is privately held, employs ~45 people across Cambridge and London, is certified to ISO 13485:2016, ISO 27001:2022, GxP and 21 CFR Part 11, and has raised approximately £8M ($11.16M) of venture funding across seed (2022), an early round (2021) and Series A (April 2024).

Short descriptiontext

Qureight is an AI-powered imaging CRO that provides proprietary deep-learning CT biomarkers, central imaging services and synthetic control arms to global biopharma sponsors running lung and heart disease clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
imaging CRO services, AI-powered imaging analytics, clinical trial endpoints, lung disease imaging, medical imaging biomarkers
Industry1 code
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Scientific Research and Development Services5417
Product category
Clinical Trial Imaging Analytics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Imaging CRO services
TypeProfessional Services
Description

End-to-end imaging CRO services for global clinical trials, including automated image management, AI analysis, central reads, and clinical trial read-outs. Recurring/contract-based revenue from biopharma sponsors across multi-year clinical trial engagements.

qureight.com
2AI-powered endpoints and analytics
TypeManaged Services
Description

Deep learning-based quantitative imaging models (Fibr8, Glass8, Air8, Vascul8, Lung8) provided as trial endpoints and analytics. Recurring revenue through clinical trial study contracts.

qureight.com
3Data science products (synthetic control arms, exploratory partnerships)
TypeProfessional Services
Description

Synthetic control arms, cohort enrichment, exploratory partnerships and enrolled cohort reporting using real-world data assets and quantitative imaging. Project-based and exploratory partnership revenue from biopharma.

qureight.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Quote-based / Not publicly disclosed
ModelOther
Notes

Enterprise contracts with biopharma; services provided as combined or standalone packages for clinical trials. No public price list.

qureight.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1Lung8
Description

AI imaging biomarker model that measures whole-lung and lobar volumes from standard-of-care inspiratory CT scans; UK registered trademark of Qureight Limited.

qureight.com
+5 more records
Core offering1 text field

Qureight is a tech-first, AI-powered imaging contract research organization (CRO) that delivers three core product lines through a proprietary data and imaging curation platform: (1) Global imaging CRO services for clinical trial image management, central reads, and site onboarding; (2) AI-powered endpoints and analytics featuring proprietary deep-learning biomarkers (Lung8, Air8, Fibr8, Glass8, Vascul8) that generate compartment-specific quantitative imaging biomarkers from standard-of-care CT scans; and (3) Data science products including synthetic control arms, cohort enrichment, and exploratory partnerships leveraging real-world datasets in IPF, PPF, PH, and Bronchiectasis. Services target global biopharma sponsors conducting clinical trials in lung and heart disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 98.4% successful CT analysis rate in peer-reviewed publications
+5 more records
Product overview1 text field

Qureight is a tech-first, AI-powered imaging contract research organization (CRO) that delivers its suite of products through a proprietary data and imaging curation platform. The offering is a platform-plus-modules architecture, with three core product lines that can be provided together or stand-alone: (1) Global imaging CRO services, the operational delivery engine for clinical trials including image management, central reads, and site onboarding; (2) AI-powered endpoints and analytics, a suite of deep learning–based quantitative imaging models including the proprietary Lung8™, Air8™, Fibr8™, Glass8™ and Vascul8™ models that generate compartment-specific biomarkers from CT scans; and (3) Data science products, which leverage Qureight's large real-world datasets in IPF, PPF, PH and Bronchiectasis to offer synthetic control arms, exploratory partnerships, cohort enrichment, and enrolled cohort reporting. Together these three lines enable sponsors to manage imaging workflows, generate AI-derived endpoints, and integrate quantitative imaging with real-world clinical data to accelerate lung and heart disease clinical trials.

Product and service3 records
1Global imaging CRO services
CategoryClinical Trial Imaging CRO Services
Description

End-to-end imaging CRO services delivered on Qureight's proprietary, high-performance platform built for speed, scalability, and reliability. Provides workflow tools to improve image handling in clinical trials, accelerating patient inclusion through infrastructure that rapidly onboards global trial sites and evaluates participants in days, not weeks. Capabilities include Radiology, Clinical Biomarkers, Data curation, Data quality control, AI image analysis, Integration, KOL advisory board, Central reads, Clinical trial read-outs, and Endpoint Discovery. Offered to global biopharma sponsors.

2AI-powered endpoints and analytics
CategoryAI-Powered Imaging Endpoints and Analytics
Description

Suite of deep-learning-based quantitative imaging models that generate compartment-specific biomarkers directly from standard-of-care inspiratory CT scans. Includes the proprietary Lung8, Air8, Fibr8, Glass8, and Vascul8 models, which track treatment response, predict disease progression and long-term clinical outcomes, and report baseline disease severity. Also provides real-time enrolment analytics for monitoring disease severity distributions in clinical trial cohorts. Purpose-built for interventional clinical trials in lung and heart disease and offered to biopharma sponsors.

3Data science products
CategoryClinical Trial Data Science Products
Description

Data-driven product line combining Qureight's commercial access to large real-world datasets in IPF, PPF, PH, and Bronchiectasis with advanced deep learning. Includes synthetic control arms, exploratory partnerships, cohort enrichment, and enrolled cohort reporting — enabling sponsors to design smarter trials, reduce placebo arm reliance, and accelerate confident development decisions. Offered to biopharma sponsors.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership22 partners
Strategic tierFlagship / High-Tier Clinical Trial PartnershipTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Qureight's AI-powered quantitative imaging analytics platform and services will be used to support Mediar Therapeutics' Phase 2 EncompaSSc clinical trial of MTX-474, a first-in-class monoclonal antibody targeting fibrosis in diffuse cutaneous Systemic Sclerosis. Qureight will use its Glass8, Fibr8, Vascul8, Air8 and Lung8 models to analyse HRCT lung images at screening and 24 weeks following treatment. The randomised, double-blind, placebo-controlled study will enroll participants in a 3:2 ratio receiving MTX-474 or placebo via intravenous infusion every four weeks, with an interim analysis at 12 weeks and end-of-treatment assessment at week 24.

Strategic tierMid-Tier Clinical Trial PartnerTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Elucidation of a drug mechanism for a biotech partner: Endeavor BioMedicines conducted a randomised, double-blind, placebo-controlled Phase 2a trial of ENV-101, a novel Hedgehog pathway inhibitor in IPF, with a hypothesised vascular mechanism. Qureight applied Vascul8 to baseline and end-of-study CT scans, demonstrating a statistically significant reduction in pulmonary vascular volume over 12 weeks in the active treatment arm compared with placebo (p=0.0007). Findings presented at ATS 2025 informed progression into Phase 2b.

Strategic tierMid-Tier Clinical Trial PartnerTypeStrategic or Co-development PartnerAnnounced on2025-08-27
Description

Qureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF).

Strategic tierMid-Tier Clinical Trial Analytics PartnerTypeStrategic or Co-development PartnerAnnounced on2025-07-15
Description

Qureight analyses of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion. Also compared baseline clinical and HRCT characteristics of Insilico's ISM001_055 Phase 2a trial cohort in China with Qureight's real-world IPF datasets.

Strategic tierMid-Tier Clinical Development PartnerTypeStrategic or Co-development PartnerAnnounced on2025-05-14
Description

Partnership to advance innovative Idiopathic Pulmonary Fibrosis (IPF) treatment research.

Strategic tierFlagship / Multi-Study Partner With High-Profile EndorsementTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF. Rein Therapeutics and Qureight have since broadened their life science collaboration. Dr Steven Shoemaker (Rein CMO) endorsed Qureight: 'Qureight delivered our first qualified imaging site just 2-3 weeks after study contract. The science is excellent — and the people may be even better.'

Strategic tierMid-Tier Early-Phase Trial PartnerTypeStrategic or Co-development PartnerAnnounced on2025-03-12
Description

Partnership to integrate Qureight's deep learning platform into Phase 1b study of RC-0315 in IPF.

Strategic tierFlagship / Long-Term Clinical Development PartnerTypeStrategic or Co-development PartnerAnnounced on2025-02-20
Description

Vicore Pharma is using Qureight's AI-powered imaging platform across multiple studies of buloxibutid for IPF, including the Phase 2b ASPIRE study. Vicore has been a long-term partner, with prior collaborations including the AIR C21 study (where Qureight created a matched synthetic control arm) and Qureight is now running AI-powered analytics across multiple Vicore assets. Vicore CMO Dr Bertil Lindmark endorses Qureight as a "real powerhouse" in lung fibrosis.

Strategic tierFlagship / Multi-Asset Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2025-02-06
Description

Strategic partnership in Progressive Pulmonary Fibrosis (PPF). Qureight's deep learning platform is being used in Avalyn's ongoing MIST study to measure treatment response, quantifying changes in fibrosis volume and across multiple compartments of the lung. Qureight is now running multiple products across multiple assets within Avalyn Pharma's portfolio. Avalyn CMO Dr Howard M. Lazarus endorses Qureight's capability to measure treatment response in PPF.

Strategic tierMid-Tier Data Ecosystem PartnerTypeTechnology or IntegrationAnnounced on2024-08-20
Description

Qureight joined OSIC and gained access to the world's largest, curated data repository for Interstitial Lung Diseases (ILDs), enhancing its real-world data and biomarker development capabilities.

Strategic tierMid-Tier Research Pilot PartnerTypeStrategic or Co-development PartnerAnnounced on2023-12-12
Description

Partnership for an Innovative Lung Transplant Research Pilot, leveraging Qureight's AI imaging platform for transplant-related research at KFSH&RC in Saudi Arabia.

Strategic tierFlagship / Strategic Tier-1 Global Pharma PartnerTypeStrategic or Co-development PartnerAnnounced on2023-07-23
Description

Multi-year research collaboration on lung disease, including the PROFILE IPF dataset. Qureight ran multiple deep learning imaging models on baseline data and combined outputs with proteomic biomarkers of interest, showing that deep learning measures of fibrosis combined with protein biomarkers of epithelial injury and collagen turnover (CYFRA21-1, SPD, ProC6) predicted mortality in IPF, independently of physiological biomarkers such as FVC. AstraZeneca has also adopted Qureight's platform for IPF research.

13patientMpower
Strategic tierMinor Collaboration PartnerTypeStrategic or Co-development PartnerAnnounced on2023-05-15
Description

Qureight is partnering with patientMpower to reveal AI insights for improved ILD (Interstitial Lung Disease) care, combining patientMpower's digital health platform with Qureight's AI imaging models.

qureight.com
14Bristol-Myers Squibb (BMS)
Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

BMS appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.

qureight.com
Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

Daiichi Sankyo appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.

Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

MSD appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.

Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

PureTech Health appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.

Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

Galecto appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.

Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

Contineum Therapeutics appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.

20Pulmongene
Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

Pulmongene appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.

qureight.com
Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

Istesso appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.

22CP (referenced as CPLogo on homepage)
Strategic tierCustomer / Enterprise BiopharmaTypeStrategic or Co-development Partner
Description

Appears as a customer logo on the Qureight website under CPLogo filename; identity refers to an enterprise biopharma partner.

qureight.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1IXICO
TypeDirect peer
Description

UK-based imaging analytics CRO that provides imaging biomarkers and central reading services for clinical trials in CNS and other indications. Directly comparable to Qureight as a technology-enabled, contract-based imaging biomarker provider serving global biopharma with proprietary AI image analysis.

TypeDirect peer
Description

French-listed imaging CRO focused on AI-driven imaging for oncology clinical trials, providing iCRO services and quantitative imaging biomarkers. Comparable to Qureight in business model (imaging CRO), customer base (global biopharma), and product offering (AI imaging biomarkers and central reads).

TypeDirect peer
Description

UK-based medical imaging company that develops AI-based quantitative imaging biomarkers for clinical trials and clinical practice, primarily in metabolic disease (liver, oncology). Directly comparable in offering AI-derived quantitative imaging endpoints to global pharma sponsors for use as trial endpoints.

TypeBroad incumbent
Description

Large, established imaging and eCOA CRO formed via the merger of Bioclinica and ERT. Provides central imaging reads, imaging management, and AI-augmented analysis across many therapeutic areas. Overlaps with Qureight in imaging CRO services but operates at significantly broader scale and indication coverage.

TypeDirect peer
Description

Imaging CRO offering central reading, AI-enabled image analysis, and imaging trial management for biopharma sponsors. Closely comparable to Qureight in service offering and customer base, with a stronger footprint in oncology and CNS imaging.

TypeEmerging player
Description

AI-for-clinical-research company applying machine learning to clinical and multi-omics data for biopharma sponsors, with growing synthetic/external control arm capabilities. Comparable to Qureight on the AI-driven trial analytics and data-science-product side, though it does not specialise in lung/cardiac imaging.

TypeEmerging player
Description

Imaging data management and AI analytics platform for clinical research, offering data curation, automated workflows, and imaging biomarkers for sponsors. Comparable to Qureight on the data curation and AI image analysis layer of clinical trial imaging workflows.

8Tempus Labs
TypeBroad incumbent
Description

Large AI-driven precision medicine company combining clinical, molecular, and imaging data for biopharma and providers. Overlaps with Qureight on AI-powered clinical trial analytics and real-world data assets but operates at vastly broader scope across oncology and many other indications.

TypeBroad incumbent
Description

Top-tier global full-service CRO with imaging and central lab capabilities across Phase 1-4 trials. Competes with Qureight for end-to-end trial sponsors that bundle imaging with broader CRO services, but lacks Qureight's depth in lung-specific AI imaging biomarkers.

TypeEmerging player
Description

Cloud-native AI imaging platform with FDA-cleared deep learning models for medical imaging analysis (originally MRI, expanding to CT). Comparable on AI imaging infrastructure and regulatory pathway, with partial overlap on CT biomarker use cases for clinical and research settings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qureight

Clinical Trial Imaging Analyticsqureight.com

Qureight is an AI-powered imaging CRO that provides proprietary deep-learning CT biomarkers, central imaging services and synthetic control arms to global biopharma sponsors running lung and heart disease clinical trials.

What Qureight does

Qureight is a Cambridge-headquartered AI-powered imaging contract research organization (CRO) that delivers deep-learning quantitative imaging biomarkers and trial-operations services to global biopharma sponsors developing therapies for lung and heart disease. Its proprietary platform processes standard-of-care inspiratory CT and CTPA scans through a suite of 3D volumetric convolutional neural networks branded as Fibr8 (fibrosis), Glass8 (inflammation), Air8 (airways), Vascul8 (pulmonary vasculature) and Lung8 (whole-lung and lobar volumes), each registered as a UK trademark and validated in peer-reviewed publications with a 98.4% successful CT analysis rate. The company also licenses what it describes as some of the largest real-world clinical and imaging datasets in idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, pulmonary hypertension and bronchiectasis, built through NHS and global data contracts and supplemented by OSIC membership, to support synthetic control arms, cohort enrichment, exploratory partnerships and enrolled-cohort reporting.

The offering is organised into three product lines: global imaging CRO services (image management, central reads, site onboarding, trial read-outs), AI-powered endpoints and analytics (the biomarker suite plus real-time enrolment analytics), and data science products (synthetic control arms, cohort enrichment, enrolled cohort reporting, exploratory partnerships). Revenue is generated through enterprise, quote-based contracts with global pharmaceutical and biotech sponsors; pricing is not publicly disclosed. Commercial momentum is evidenced by a customer base of 17+ named biopharma sponsors — including AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, MSD, Vicore Pharma, Avalyn, Mediar, Calluna, Rein Therapeutics, Cumberland Pharmaceuticals, Insilico Medicine and Endeavor BioMedicines — across multiple Phase 2 programmes in IPF, PPF, PH, systemic sclerosis and bronchiectasis. The company is privately held, employs ~45 people across Cambridge and London, is certified to ISO 13485:2016, ISO 27001:2022, GxP and 21 CFR Part 11, and has raised approximately £8M ($11.16M) of venture funding across seed (2022), an early round (2021) and Series A (April 2024).

Qureight firmographics

Firmographics
Name
Qureight
Legal name
Qureight Limited
Website
https://qureight.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Qureight is an AI-powered imaging CRO that provides proprietary deep-learning CT biomarkers, central imaging services and synthetic control arms to global biopharma sponsors running lung and heart disease clinical trials.
Ownership category
akta.pro rank

Qureight industry classification

Industry
Product category
Clinical Trial Imaging Analytics
NAICS
Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Imaging CRO services
  • AI-powered imaging analytics
  • Clinical trial endpoints
  • Lung disease imaging
  • Medical imaging biomarkers

Where Qureight is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Qureight business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Imaging CRO services: End-to-end imaging CRO services for global clinical trials, including automated image management, AI analysis, central reads, and clinical trial read-outs. Recurring/contract-based revenue from biopharma sponsors across multi-year clinical trial engagements.
  2. AI-powered endpoints and analytics: Deep learning-based quantitative imaging models (Fibr8, Glass8, Air8, Vascul8, Lung8) provided as trial endpoints and analytics. Recurring revenue through clinical trial study contracts.
  3. Data science products (synthetic control arms, exploratory partnerships): Synthetic control arms, cohort enrichment, exploratory partnerships and enrolled cohort reporting using real-world data assets and quantitative imaging. Project-based and exploratory partnership revenue from biopharma.

Pricing tiers

ModelBillingPrice
Other—Quote-based / Not publicly disclosed

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Qureight product offering

Product offering

Core offering

Qureight is a tech-first, AI-powered imaging contract research organization (CRO) that delivers three core product lines through a proprietary data and imaging curation platform: (1) Global imaging CRO services for clinical trial image management, central reads, and site onboarding; (2) AI-powered endpoints and analytics featuring proprietary deep-learning biomarkers (Lung8, Air8, Fibr8, Glass8, Vascul8) that generate compartment-specific quantitative imaging biomarkers from standard-of-care CT scans; and (3) Data science products including synthetic control arms, cohort enrichment, and exploratory partnerships leveraging real-world datasets in IPF, PPF, PH, and Bronchiectasis. Services target global biopharma sponsors conducting clinical trials in lung and heart disease.

Product overview

Qureight is a tech-first, AI-powered imaging contract research organization (CRO) that delivers its suite of products through a proprietary data and imaging curation platform. The offering is a platform-plus-modules architecture, with three core product lines that can be provided together or stand-alone: (1) Global imaging CRO services, the operational delivery engine for clinical trials including image management, central reads, and site onboarding; (2) AI-powered endpoints and analytics, a suite of deep learning–based quantitative imaging models including the proprietary Lung8™, Air8™, Fibr8™, Glass8™ and Vascul8™ models that generate compartment-specific biomarkers from CT scans; and (3) Data science products, which leverage Qureight's large real-world datasets in IPF, PPF, PH and Bronchiectasis to offer synthetic control arms, exploratory partnerships, cohort enrichment, and enrolled cohort reporting. Together these three lines enable sponsors to manage imaging workflows, generate AI-derived endpoints, and integrate quantitative imaging with real-world clinical data to accelerate lung and heart disease clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • Lung8: AI imaging biomarker model that measures whole-lung and lobar volumes from standard-of-care inspiratory CT scans; UK registered trademark of Qureight Limited.
  • Air8
  • Fibr8
  • Glass8
  • Vascul8
  • Lobe8

Products and services

  • Global imaging CRO services End-to-end imaging CRO services delivered on Qureight's proprietary, high-performance platform built for speed, scalability, and reliability. Provides workflow tools to improve image handling in clinical trials, accelerating patient inclusion through infrastructure that rapidly onboards global trial sites and evaluates participants in days, not weeks. Capabilities include Radiology, Clinical Biomarkers, Data curation, Data quality control, AI image analysis, Integration, KOL advisory board, Central reads, Clinical trial read-outs, and Endpoint Discovery. Offered to global biopharma sponsors.
  • AI-powered endpoints and analytics Suite of deep-learning-based quantitative imaging models that generate compartment-specific biomarkers directly from standard-of-care inspiratory CT scans. Includes the proprietary Lung8, Air8, Fibr8, Glass8, and Vascul8 models, which track treatment response, predict disease progression and long-term clinical outcomes, and report baseline disease severity. Also provides real-time enrolment analytics for monitoring disease severity distributions in clinical trial cohorts. Purpose-built for interventional clinical trials in lung and heart disease and offered to biopharma sponsors.
  • Data science products Data-driven product line combining Qureight's commercial access to large real-world datasets in IPF, PPF, PH, and Bronchiectasis with advanced deep learning. Includes synthetic control arms, exploratory partnerships, cohort enrichment, and enrolled cohort reporting — enabling sponsors to design smarter trials, reduce placebo arm reliance, and accelerate confident development decisions. Offered to biopharma sponsors.

Quantifiable outcome

  • 98.4% successful CT analysis rate in peer-reviewed publications
  • +5 more outcomes

Companies that use Qureight

Customer profile

Ideal customer profiles2 records

Qureight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

Qureight partnerships and signals

Strategic signal

Partnerships

22 partnerships are on record, tiered flagship / high-tier clinical trial partnership, mid-tier clinical trial partner, mid-tier clinical trial analytics partner, mid-tier clinical development partner, flagship / multi-study partner with high-profile endorsement, mid-tier early-phase trial partner, flagship / long-term clinical development partner, flagship / multi-asset strategic partner, mid-tier data ecosystem partner, mid-tier research pilot partner, flagship / strategic tier-1 global pharma partner, minor collaboration partner and customer / enterprise biopharma.

  • Mediar Therapeuticsflagship / high-tier clinical trial partnershipStrategic or Co-development Partner · 13 May 2026Qureight's AI-powered quantitative imaging analytics platform and services will be used to support Mediar Therapeutics' Phase 2 EncompaSSc clinical trial of MTX-474, a first-in-class monoclonal antibody targeting fibrosis in diffuse cutaneous Systemic Sclerosis. Qureight will use its Glass8, Fibr8, Vascul8, Air8 and Lung8 models to analyse HRCT lung images at screening and 24 weeks following treatment. The randomised, double-blind, placebo-controlled study will enroll participants in a 3:2 ratio receiving MTX-474 or placebo via intravenous infusion every four weeks, with an interim analysis at 12 weeks and end-of-treatment assessment at week 24.
  • Endeavor BioMedicinesmid-tier clinical trial partnerStrategic or Co-development Partner · 13 May 2026Elucidation of a drug mechanism for a biotech partner: Endeavor BioMedicines conducted a randomised, double-blind, placebo-controlled Phase 2a trial of ENV-101, a novel Hedgehog pathway inhibitor in IPF, with a hypothesised vascular mechanism. Qureight applied Vascul8 to baseline and end-of-study CT scans, demonstrating a statistically significant reduction in pulmonary vascular volume over 12 weeks in the active treatment arm compared with placebo (p=0.0007). Findings presented at ATS 2025 informed progression into Phase 2b.
  • Calluna Pharmamid-tier clinical trial partnerStrategic or Co-development Partner · 27 August 2025Qureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF).
  • Insilico Medicinemid-tier clinical trial analytics partnerStrategic or Co-development Partner · 15 July 2025Qureight analyses of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion. Also compared baseline clinical and HRCT characteristics of Insilico's ISM001_055 Phase 2a trial cohort in China with Qureight's real-world IPF datasets.
  • Cumberland Pharmaceuticalsmid-tier clinical development partnerStrategic or Co-development Partner · 14 May 2025Partnership to advance innovative Idiopathic Pulmonary Fibrosis (IPF) treatment research.
  • Rein Therapeuticsflagship / multi-study partner with high-profile endorsementStrategic or Co-development Partner · 1 May 2025Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF. Rein Therapeutics and Qureight have since broadened their life science collaboration. Dr Steven Shoemaker (Rein CMO) endorsed Qureight: 'Qureight delivered our first qualified imaging site just 2-3 weeks after study contract. The science is excellent — and the people may be even better.'
  • Remedy Cellmid-tier early-phase trial partnerStrategic or Co-development Partner · 12 March 2025Partnership to integrate Qureight's deep learning platform into Phase 1b study of RC-0315 in IPF.
  • Vicore Pharmaflagship / long-term clinical development partnerStrategic or Co-development Partner · 20 February 2025Vicore Pharma is using Qureight's AI-powered imaging platform across multiple studies of buloxibutid for IPF, including the Phase 2b ASPIRE study. Vicore has been a long-term partner, with prior collaborations including the AIR C21 study (where Qureight created a matched synthetic control arm) and Qureight is now running AI-powered analytics across multiple Vicore assets. Vicore CMO Dr Bertil Lindmark endorses Qureight as a "real powerhouse" in lung fibrosis.
  • Avalyn Pharmaflagship / multi-asset strategic partnerStrategic or Co-development Partner · 6 February 2025Strategic partnership in Progressive Pulmonary Fibrosis (PPF). Qureight's deep learning platform is being used in Avalyn's ongoing MIST study to measure treatment response, quantifying changes in fibrosis volume and across multiple compartments of the lung. Qureight is now running multiple products across multiple assets within Avalyn Pharma's portfolio. Avalyn CMO Dr Howard M. Lazarus endorses Qureight's capability to measure treatment response in PPF.
  • Open Source Imaging Consortium (OSIC)mid-tier data ecosystem partnerTechnology or Integration · 20 August 2024Qureight joined OSIC and gained access to the world's largest, curated data repository for Interstitial Lung Diseases (ILDs), enhancing its real-world data and biomarker development capabilities.
  • King Faisal Specialist Hospital and Research Centremid-tier research pilot partnerStrategic or Co-development Partner · 12 December 2023Partnership for an Innovative Lung Transplant Research Pilot, leveraging Qureight's AI imaging platform for transplant-related research at KFSH&RC in Saudi Arabia.
  • AstraZenecaflagship / strategic tier-1 global pharma partnerStrategic or Co-development Partner · 23 July 2023Multi-year research collaboration on lung disease, including the PROFILE IPF dataset. Qureight ran multiple deep learning imaging models on baseline data and combined outputs with proteomic biomarkers of interest, showing that deep learning measures of fibrosis combined with protein biomarkers of epithelial injury and collagen turnover (CYFRA21-1, SPD, ProC6) predicted mortality in IPF, independently of physiological biomarkers such as FVC. AstraZeneca has also adopted Qureight's platform for IPF research.
  • patientMpowerminor collaboration partnerStrategic or Co-development Partner · 15 May 2023Qureight is partnering with patientMpower to reveal AI insights for improved ILD (Interstitial Lung Disease) care, combining patientMpower's digital health platform with Qureight's AI imaging models.
  • Bristol-Myers Squibb (BMS)customer / enterprise biopharmaStrategic or Co-development PartnerBMS appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
  • Daiichi Sankyocustomer / enterprise biopharmaStrategic or Co-development PartnerDaiichi Sankyo appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
  • MSD (Merck Sharp & Dohme)customer / enterprise biopharmaStrategic or Co-development PartnerMSD appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
  • PureTech Healthcustomer / enterprise biopharmaStrategic or Co-development PartnerPureTech Health appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
  • Galectocustomer / enterprise biopharmaStrategic or Co-development PartnerGalecto appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
  • Contineum Therapeuticscustomer / enterprise biopharmaStrategic or Co-development PartnerContineum Therapeutics appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
  • Pulmongenecustomer / enterprise biopharmaStrategic or Co-development PartnerPulmongene appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
  • Istessocustomer / enterprise biopharmaStrategic or Co-development PartnerIstesso appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
  • CP (referenced as CPLogo on homepage)customer / enterprise biopharmaStrategic or Co-development PartnerAppears as a customer logo on the Qureight website under CPLogo filename; identity refers to an enterprise biopharma partner.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Qureight competitors and assessment

Company assessment

Direct peers

  • IXICO: UK-based imaging analytics CRO that provides imaging biomarkers and central reading services for clinical trials in CNS and other indications. Directly comparable to Qureight as a technology-enabled, contract-based imaging biomarker provider serving global biopharma with proprietary AI image analysis.
  • Median Technologies: French-listed imaging CRO focused on AI-driven imaging for oncology clinical trials, providing iCRO services and quantitative imaging biomarkers. Comparable to Qureight in business model (imaging CRO), customer base (global biopharma), and product offering (AI imaging biomarkers and central reads).
  • Perspectum: UK-based medical imaging company that develops AI-based quantitative imaging biomarkers for clinical trials and clinical practice, primarily in metabolic disease (liver, oncology). Directly comparable in offering AI-derived quantitative imaging endpoints to global pharma sponsors for use as trial endpoints.
  • Calyx (formerly Image Analysis Group): Imaging CRO offering central reading, AI-enabled image analysis, and imaging trial management for biopharma sponsors. Closely comparable to Qureight in service offering and customer base, with a stronger footprint in oncology and CNS imaging.

Broad incumbents

  • Clario: Large, established imaging and eCOA CRO formed via the merger of Bioclinica and ERT. Provides central imaging reads, imaging management, and AI-augmented analysis across many therapeutic areas. Overlaps with Qureight in imaging CRO services but operates at significantly broader scale and indication coverage.
  • Tempus Labs: Large AI-driven precision medicine company combining clinical, molecular, and imaging data for biopharma and providers. Overlaps with Qureight on AI-powered clinical trial analytics and real-world data assets but operates at vastly broader scope across oncology and many other indications.
  • PAREXEL (or any major broad CRO with imaging arm): Top-tier global full-service CRO with imaging and central lab capabilities across Phase 1-4 trials. Competes with Qureight for end-to-end trial sponsors that bundle imaging with broader CRO services, but lacks Qureight's depth in lung-specific AI imaging biomarkers.

Emerging players

  • Owkin: AI-for-clinical-research company applying machine learning to clinical and multi-omics data for biopharma sponsors, with growing synthetic/external control arm capabilities. Comparable to Qureight on the AI-driven trial analytics and data-science-product side, though it does not specialise in lung/cardiac imaging.
  • Flywheel: Imaging data management and AI analytics platform for clinical research, offering data curation, automated workflows, and imaging biomarkers for sponsors. Comparable to Qureight on the data curation and AI image analysis layer of clinical trial imaging workflows.
  • Arterys: Cloud-native AI imaging platform with FDA-cleared deep learning models for medical imaging analysis (originally MRI, expanding to CT). Comparable on AI imaging infrastructure and regulatory pathway, with partial overlap on CT biomarker use cases for clinical and research settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Qureight social profiles

Digital presence

Qureight compliance and trust

Trust signal

Compliance5 records

Qureight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qureight leadership team

Management profile

Number of profiles

Profiles10 records

Qureight funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qureight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qureight

What does Qureight do?

Qureight is a tech-first, AI-powered imaging contract research organization (CRO) that delivers three core product lines through a proprietary data and imaging curation platform: (1) Global imaging CRO services for clinical trial image management, central reads, and site onboarding; (2) AI-powered endpoints and analytics featuring proprietary deep-learning biomarkers (Lung8, Air8, Fibr8, Glass8, Vascul8) that generate compartment-specific quantitative imaging biomarkers from standard-of-care CT scans; and (3) Data science products including synthetic control arms, cohort enrichment, and exploratory partnerships leveraging real-world datasets in IPF, PPF, PH, and Bronchiectasis. Services target global biopharma sponsors conducting clinical trials in lung and heart disease.

Is Qureight a public or private company?

Qureight is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qureight founded?

Qureight was founded in 2018. It employs 51 to 100 people.

Where is Qureight based?

Qureight is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Qureight make money?

Three revenue lines are on record. Imaging CRO services are the primary driver. The others are AI-powered endpoints and analytics and data science products (synthetic control arms, exploratory partnerships).

Who are Qureight's main competitors?

Direct peers on record are IXICO, Median Technologies, Perspectum and Calyx (formerly Image Analysis Group). Broad incumbents are Clario, Tempus Labs and PAREXEL (or any major broad CRO with imaging arm). Emerging players are Owkin, Flywheel and Arterys.

Does Qureight have an API?

No public API is recorded for Qureight.

What industry is Qureight in?

Qureight's product category is Clinical Trial Imaging Analytics. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 5417.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalQureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trialQureight's Fibr8 imaging biomarker is a secondary endpoint in Contineum's PROPEL-IPF Phase 2 trial of PIPE-791 for idiopathic pulmonary fibrosis. The trial uses FVC as primary endpoint and Fibr8 to measure fibrosis on HRCT, potentially generating evidence for imaging endpoints in future trials.News-MedicalQureight's fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trialQureight's Fibr8 imaging biomarker will be a secondary endpoint in Contineum's PROPEL-IPF Phase 2 trial of PIPE-791 for idiopathic pulmonary fibrosis. The trial uses FVC as primary endpoint and aims to assess treatment effects on both lung function and fibrosis progression. Results could support regulatory qualification of imaging biomarkers for antifibrotic trials.YahooQureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical TrialQureight's Fibr8 imaging biomarker will serve as a secondary endpoint in Contineum's Phase 2 PROPEL-IPF trial of PIPE-791 for idiopathic pulmonary fibrosis. The trial, evaluating safety and efficacy in about 324 patients, uses Fibr8 to measure fibrosis on HRCT alongside forced vital capacity. Results may support regulatory qualification of imaging endpoints.Stock TitanContineum Adds Qureight Fibrosis Measure as Phase 2 EndpointQureight's Fibr8 imaging biomarker will be a secondary endpoint in Contineum's Phase 2 PROPEL-IPF trial of PIPE-791 for idiopathic pulmonary fibrosis. The trial pairs FVC with HRCT fibrosis measurements to assess treatment effects on both lung function and structural disease burden.FinancialContent Business PageQureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical TrialQureight's Fibr8 imaging biomarker will serve as a secondary endpoint in Contineum's Phase 2 PROPEL-IPF trial of PIPE-791 for idiopathic pulmonary fibrosis. The trial, with about 324 patients, uses FVC as primary endpoint and aims to generate evidence for imaging endpoints in antifibrotic trials.News-MedicalQureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trialsQureight published a Viewpoint in the European Respiratory Journal arguing that fibrosis extent on HRCT should be the principal structural imaging biomarker in antifibrotic trials. The paper contends that current FVC endpoints are downstream and that direct measurement of scar tissue could complement them. It notes that more robust evidence is needed for fibrosis burden to become a surrogate endpoint.News-MedicalImaging CRO qureight supports celea's SURPASS-IPF trialQureight was selected by Celea Therapeutics as imaging CRO for the Phase 3 SURPASS-IPF trial of deupirfenidone. The trial will compare deupirfenidone to pirfenidone over 52 weeks. Qureight will present a joint poster at CHEST 2026 on ELEVATE-IPF imaging analysis.BusinessinsiderLa regulación amenaza con convertirse en el mayor desafío para la IA sanitaria europeaEuropean health AI startups face regulatory hurdles from the EU AI Act, which adds obligations on top of existing medical device rules. The duplication of audits under the AI Act and MDR/IVDR threatens to slow innovation and raise costs, with a 2027-2028 transition period. The EU aims to simplify via the Digital Omnibus, but concerns remain about competitiveness.News-MedicalQureight expands with addition of second site, to accommodate rapid growth and ongoing development of chest Foundation ModelQureight has opened a second office in London, UK, to support its rapid growth and the development of its chest Foundation Model for AI-powered imaging. This expansion allows the company to accommodate an increase in staff from 15 to 60 full-time equivalents and hire machine learning experts to serve global biopharma clients.Nelson Advisors BlogThis Week in European HealthTech, MedTech and Health AI: 14th August 2026The European HealthTech, MedTech, and Health AI sectors are experiencing significant developments, including the enforcement of the EU AI Act and the introduction of a fast-track pathway by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Key funding rounds have been reported, focusing on deep-tech diagnostics and clinical infrastructure, with notable investments in companies like Qureight and Ahead Health. Additionally, consolidation trends are seen in the biopharma sector, particularly with Clean Cells acquiring Anaquant.